WHO Call for Consultation: Preferred product characteristics for medicines for malaria chemoprevention
The WHO Global Malaria Programme (GMP) is seeking public comments on the following preferred product characteristics (PPCs) for medicines for malaria chemoprevention. PPCs are becoming a key tool for WHO to incentivize and guide the development of urgently needed health products.
WHO’s PPCs aim to:
- communicate unmet public health needs;
- stimulate the development of relevant new products to meet those needs; and
- facilitate the timely assessment of new products, and the formulation of policy recommendations and prequalification listings.
This PPC builds on a WHO technical consultation held in December 2020, which considered key characteristics of medicines for use in malaria chemoprevention. These include the indication, target population, safety and efficacy, formulation and presentation, dose regimen, co-administration, route of administration, product stability and storage, and access and affordability. The preferences and related considerations are shaped by the unmet public health needs and the realities of malaria epidemiology and delivery systems in target geographies.
Interested parties can provide comments using the following online survey
Read more here.
Consultation deadline August 22, 2022.
